SR-17018 and
Opioid Withdrawal: What Happens Now?
The research was real. The treatment claims went much further than the evidence.
The Research Was Real. The “Detox Cure” Wasn't Proven.
SR-17018 attracted attention because early animal research suggested it might reduce opioid withdrawal. For someone worried about stopping opioids, it is easy to understand why that sounded promising.
But SR-17018 remained an experimental research compound. It was never FDA-approved for human use, and human clinical trials had not established how reliably it worked for withdrawal, what dose should be used, or what risks might emerge outside controlled research.
SR-17018 Is Now Temporarily Schedule I
On August 27, 2026, the DEA temporarily placed SR-17018 into Schedule I. If it was part of your plan for getting through opioid withdrawal, the practical question is now: What are my options instead?
A private way to get through withdrawal without checking into a hospital, going away to rehab, or putting work and family on hold.
Why Did SR-17018 Get So Much Attention?
Interest in compounds like SR-17018 grew quickly online. Promising laboratory findings, personal success stories and the appeal of managing withdrawal outside a traditional treatment setting made the idea especially attractive.
But promising research and an established human treatment are not the same thing.
Getting through withdrawal is a goal. It is not the same thing as proving that an experimental compound is safe or effective treatment.
What Were People Actually Taking?
Laboratory research on a defined compound and a finished product purchased online are not necessarily the same thing.
You Were Looking for a Way to Get Help Without Going Away.
For appropriate patients, opioid treatment can often begin without checking into a hospital or leaving home for a traditional detox or rehab program. That is what office-based treatment was designed to do.
If what attracted you to SR-17018 was the possibility of getting through withdrawal without going away for treatment, that option didn't disappear when SR-17018 did.
Reach Out
Start with private contact and rapid scheduling rather than navigating a large treatment program.
Meet With a Physician
Review what you are using, withdrawal risk, medical history and the treatment options available.
Start Treatment
Established medications can be used when medically appropriate instead of relying on an experimental compound.
Keep Living Your Life
Continue working, caring for family and handling everyday responsibilities while receiving ongoing care.
There Is More Than One Way to Move Forward.
Withdrawal management may be the first step. Depending on your goals, ongoing treatment can include oral buprenorphine or long-acting options such as Brixadi or Sublocade.
Learn about physician-supervised withdrawal management and what can happen after withdrawal is controlled.
LONG-ACTING BUPRENORPHINE Learn About Brixadi →Weekly and monthly long-acting buprenorphine treatment for opioid use disorder.
LONG-ACTING TREATMENT Brixadi vs. Sublocade →Compare the long-acting injection options and understand how they differ.
Getting Through Withdrawal Is an Important First Step. It Doesn't Have to Be the Last.
For many people, the attraction of SR-17018 was the possibility of getting through withdrawal without a hospital stay, going away to rehab, or putting everyday life on hold.
Going through withdrawal is not necessarily a cure. It is an important first step on the road to recovery. For those who want to take that step, we have established treatment options that can often be managed through office-based care.
More importantly, we'll still be here after treatment is completed. The same physician who helps you get started can continue working with you afterward—helping you decide what comes next and making sure you're still heading in the right direction.
Schedule an Appointment
Learn what office-based treatment options may be available to you— for managing withdrawal and for what comes next.
Schedule an Appointment →